
feb pm et
summari compani one world largest drug maker larg small molecul
price-to-earnings oper ep
risk assess reflect challeng brand
patent new drug develop regulatori risk
believ rel robust pipelin
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
see modest sale growth
billion billion solid sale
immuno-therapi drug keytruda off-set flat
growth januvia janumet lower
sale cubicin zetia octob
keytruda approv non-smal cell lung
cancer nsclc first line treatment
patient express
greater second line treatment
patient express may
fda approv use keytruda
combin chemotherapi pemetrex
carboplatin treat advanc lung cancer
also may keytruda also approv
treat bladder cancer keytruda approv
nsclc metastat melanoma head
neck cancer bladder cancer see
sale billion
billion
octob withdrew european
applic keytruda combin
chemotherapi first line treatment
non-smal cell lung cancer indic
modifi phase trial overal
surviv progression-fre surviv
believ delay trial result
see ep
octob keytruda approv
first line treatment nsclc see
establish larg market share
approv immuno-oncolog drug first
line set howev see
withdraw european applic
keytruda combin chemotherapi
setback also januari agre
pay bristol-my squibb
up-front fee along
royalti global keytruda sale
relat
patent litig think share
trade forward ep
estim peer near fair
valu see limit sale growth spite
patent exclus decemb
forecast sale declin billion
billion
risk opinion target price includ
possibl pipelin setback
target base
in-lin peer forward
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview merck co lead global drugmak produc wide rang prescript
drug mani therapeut class abroad foreign oper account
total sale respect
early-novemb acquir rival drugmak schering-plough billion cash
largest-sel product includ januvia/janumet sale billion billion
treatment type diabet remicad billion billion
treatment rheumatoid arthriti isentress billio billion treatment
hiv/aid remicad lost patent protect europ late
merck also lead maker vaccin vaccin includ proquad measl mump rubella
chicken pox gardasil human papilloma viru main caus cervic cancer rotateq
purchas schering-plough merck gain total right zetia -- cholesterol therapi
work block cholesterol absorpt intestin -- well vytorin combin pill
contain zocor zetia vytorin sale billion billion
zetia sale billion billion anim health product compris
anti-infect antiparasit drug relat item octob merck sold consum care
product unit includ over-the-counter brand claritin allergi dr scholl foot care product
copperton suntan lotion bayer ag billion
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate period accord forecast made im health
key driver emerg market whose aggreg sale countri advanc compound-annual-growth-rate
period growth develop market spur rise standard
live grow govern spend health care howev im forecast declin trend europ
impact auster price combin drug spend five major european market project
declin compound-annual-growth-rate hand spend forecast
grow compound-annual-growth-rate period
impact major develop expens total billion sale billion
sale billion sale pipelin august
includ five program regulatori review program phase clinic trial program
phase ii clinic trial billion acquisit schering-plough fund cash
billion debt billion merck stock billion octob
complet sale consum care unit includ brand claritin afrin copperton
bayer ag billion
presid financ
chief offic
global servic
offic presid
gener counsel
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri howev
number new molecular entiti approv
declin robust approv
sinc record
approv follow robust approv
approv
 pharmaceut index
declin versu rise
composit index year-to-d
juli pharmaceut index
declin vs rise
fundament outlook pharmaceut
sub-industri next month posit
top-lin pressur patent expir
mani top-sel drug bottom
anticip modest sale increas
follow growth see
modest advers impact foreign exchang
follow firm
 dollar late also see
expand sale new innov drug
therapi margin improv accru
cost restructur merger synergi ep
comparison also benefit common
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev presid trump republican
made effort repeal replac
arr uncertain compon
surviv particularli individu
mandat medicaid expans may
hous repres pass
ahca would result million
peopl uninsur compar
june senat unveil healthcar
plan better reconcili act
bcra howev senat yet vote
bill cbo estim million
peopl would uninsur compar
hous senat plan would
elimin individu mandat phase
medicaid expans
despit advers effect patent expir
regulatori pressur high drug price
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
astrazeneca includ co-promot lynparza /jeffrey loo cfa
rais target price in-lin
peer forward ep estim ep vs
ahead estim rais ep estim
sale rose ahead forecast declin driven
robust increas keytruda sale offset
declin sever older key drug januvia
zetia/vytorin look continu robust rise keytruda sale
approv addit oncolog indic /jeffrey loo cfa
keep target in-lin peer
ep estim ep vs in-lin
estim sale rose keytruda sale doubl
forecast sever regulatori action date year
includ fda action date may keytruda combin
chemotherapi treat advanc non-smal cell lung cancer june
keytruda treat bladder cancer anticip fda approv
indic help drive keytruda sale /jeffrey loo cfa
merck announc plan retir robert kidder board
retir take place connect annual meet sharehold
et capit iq keep hold opinion share merck
 co keep target in-lin peer
ep estim set ep
estim ep vs ahead estim
sale fell robust keytruda sale off-set declin drug
includ cubicin zetia guid sale flat
ep although see grow keytruda sale
approv new indic sale key drug like declin
keytruda fda action date indic next month
analyst research note compani news
keep target price slightli
peer ep estim set ep
ep vs ahead estim aid lower tax
rate sale rose slightli forecast keytruda sale
solid view guid sale ep
look continu robust sale keytruda recent approv
lynparza co-partn astrazeneca treat breast cancer
anticip flat sale top sell diabet drug januvia /jeffrey loo
merck appoint dirk toepfer new chief inform offic
effect march toepfer report udit ceo life scienc
member execut board respons group function
busi technolog among thing dirk toepfer succe jim stewart
head merck busi servic mb proven track record
success manag large-scal transform initi well
physic also dortmund univers earn doctor work
desi deutsch elektronen-synchrotron institut hamburg began
profession career project manag bertelsmann mediasystem
lastli respons bertelsmann global infrastructur
join metro group manag director later ceo
servic compani metro system consolid intern system
restructur organ establish major off-shore capabl
merck announc ing thulin chairman board presid chief
execut offic join compani board director
effect march mr thulin stand elect
compani director connect merck annual meet
sharehold may addit mr thulin merck
board includ member
share significantli posit phase
result keytruda combin two chemotherapi drug first
line treatment non-smal cell lung cancer trial met
endpoint overal surviv progression-fre surviv result
submit regul believ bolster chanc approv
europ solidifi lead posit indic
withdrawn eu applic oct trial
meet endpoint fda approv alreadi receiv set /jeffrey
lower target below-p
forward ep estim share
eu file keytruda combin chemotherapi first line
treatment non-smal cell lung cancer fda approv given
set may said modifi phase trial overal
surviv progression-fre surviv believ delay result
see lung cancer among import oncolog indic
see potenti benefit competitor bristol-mey opdivo /jeffrey
keep target price in-lin
forward ep estim ep vs
ahead estim rais ep estim
sale fell partli unfavor impact cyber attack june
say result lost sale ad cost separ
keytruda sale exceed think new indic
drive sale also encourag oncolog collabor
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
